{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:20:51Z","timestamp":1782991251910,"version":"3.54.5"},"reference-count":65,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"unspecified","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,7,11]]},"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Opioid use disorder (OUD) during pregnancy is associated with increased rates of adverse perinatal, foetal and neonatal health events. Opioid agonist treatment (OAT) can substantially reduce the risk of these potential harms. In British Columbia (BC), methadone and buprenorphine\/naloxone are first-line treatment options for pregnant people with OUD. However, the comparative effectiveness of these regimens during pregnancy remains poorly understood, particularly in terms of how dosage may impact clinical outcomes. This protocol outlines a proposed population-based retrospective study to evaluate the comparative effectiveness of methadone compared with buprenorphine\/naloxone during pregnancy on perinatal and neonatal health outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>We propose to conduct a retrospective observational study using population-based data from individuals who received methadone or buprenorphine\/naloxone during pregnancy between 1 April 2010 and 31 March 2022. Data will be collected from 10 linked population-level administrative databases. We will emulate target trials using intention-to-treat and per-protocol approaches. We will use a pooled logistic regression approach to assess the impact of methadone versus buprenorphine\/naloxone on time to OAT episode discontinuation and a dose-response marginal structural model to evaluate neonatal health at delivery. An exploratory observational analysis will also be conducted to describe the impact of methadone vs buprenorphine exposure during the first trimester of pregnancy on congenital malformations and anomalies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This study has been determined to meet the criteria for exemption per Article 2.5 of the 2018 Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans. Study databases have been made available by the BC Ministries of Health and Mental Health and Addiction as part of the provincial opioid overdose public health emergency response. Results will be disseminated to policymakers, clinical partners, community programmes and people with lived and living experience of substance use and published in peer-reviewed journals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-095461","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T02:36:10Z","timestamp":1754879770000},"page":"e095461","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Comparative effectiveness of methadone versus buprenorphine\/naloxone during pregnancy on perinatal and neonatal health outcomes: protocol for a population-based target trial in British Columbia, Canada"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9910-3338","authenticated-orcid":false,"given":"Lindsay A","family":"Wilson","sequence":"first","affiliation":[{"name":"School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Kurz","sequence":"additional","affiliation":[{"name":"Centre for Advancing Health Outcomes, Vancouver, British Columbia, Canada"},{"name":"Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B Carolina","family":"Guerra-Alejos","sequence":"additional","affiliation":[{"name":"Centre for Advancing Health Outcomes, Vancouver, British Columbia, Canada"},{"name":"Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0968-722X","authenticated-orcid":false,"given":"Jeong Eun","family":"Min","sequence":"additional","affiliation":[{"name":"Centre for Advancing Health Outcomes, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianping","family":"Ti","sequence":"additional","affiliation":[{"name":"British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada"},{"name":"Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2513-3718","authenticated-orcid":false,"given":"Bohdan","family":"Nosyk","sequence":"additional","affiliation":[{"name":"Centre for Advancing Health Outcomes, Vancouver, British Columbia, Canada"},{"name":"Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,8,10]]},"reference":[{"key":"2025123106455714000_15.8.e095461.1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/AOG.0000000000001446","article-title":"Opioid Use Disorder in Pregnancy: Health Policy and Practice in the Midst of an Epidemic","volume":"128","author":"Krans","year":"2016","journal-title":"Obstet Gynecol"},{"key":"2025123106455714000_15.8.e095461.2","doi-asserted-by":"crossref","first-page":"906723","DOI":"10.1155\/2014\/906723","article-title":"Maternal opioid drug use during pregnancy and its impact on perinatal morbidity, mortality, and the costs of medical care in the United States","volume":"2014","author":"Whiteman","year":"2014","journal-title":"J Pregnancy"},{"key":"2025123106455714000_15.8.e095461.3","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.8256","article-title":"Association of Maternal Opioid Use in Pregnancy With Adverse Perinatal Outcomes in Ontario, Canada, From 2012 to 2018","volume":"3","author":"Corsi","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2025123106455714000_15.8.e095461.4","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000004649"},{"key":"2025123106455714000_15.8.e095461.5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ajog.2018.09.028","article-title":"Trends in pregnancy-associated mortality involving opioids in the United States, 2007\u20132016","volume":"220","author":"Gemmill","year":"2019","journal-title":"Am J Obstet Gynecol"},{"key":"2025123106455714000_15.8.e095461.6","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1001\/jama.2022.17045","article-title":"US Trends in Drug Overdose Mortality Among Pregnant and Postpartum Persons, 2017-2020","volume":"328","author":"Bruzelius","year":"2022","journal-title":"JAMA"},{"key":"2025123106455714000_15.8.e095461.7","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.drugalcdep.2017.12.019","article-title":"Trends in incidence of neonatal abstinence syndrome in Canada and associated healthcare resource utilization","volume":"185","author":"Filteau","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"2025123106455714000_15.8.e095461.8","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2021-050279","article-title":"Opioid Use Disorder and Perinatal Outcomes","volume":"148","author":"Piske","year":"2021","journal-title":"Pediatrics"},{"key":"2025123106455714000_15.8.e095461.9","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ajog.2016.10.003","article-title":"Opioid dependence and pregnancy: minimizing stress on the fetal brain","volume":"216","author":"McCarthy","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"2025123106455714000_15.8.e095461.10","unstructured":"American College of Obstetricians and Gynecologists . Committee opinion: opioid use and opioid use disorder in pregnancy. ACOG Clinical; 2017. Available: https:\/\/www.acog.org\/en\/clinical\/clinical-guidance\/committee-opinion\/articles\/2017\/08\/opioid-use-and-opioid-use-disorder-in-pregnancy [Accessed 03 Oct 2022]."},{"key":"2025123106455714000_15.8.e095461.11","unstructured":"British Columbia Ministry of Health, Perinatal Services BC, British Columbia Centre on Substance Use . A guideline for the clinical management of opioid use disorder- pregnancy supplement. Canada British Columbia; 2018."},{"key":"2025123106455714000_15.8.e095461.12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/08897077.2012.752779","article-title":"Treating Opioid Use Disorders during Pregnancy: Historical, Current, and Future Directions","volume":"34","author":"Jones","year":"2013","journal-title":"Subst Abuse"},{"key":"2025123106455714000_15.8.e095461.13","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1111\/add.15818","article-title":"Clinical Management of Opioid Withdrawal","volume":"117","author":"Torres-Lockhart","year":"2022","journal-title":"Addiction"},{"key":"2025123106455714000_15.8.e095461.14","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.170958"},{"key":"2025123106455714000_15.8.e095461.15","doi-asserted-by":"publisher","DOI":"10.1177\/1060028016648367"},{"key":"2025123106455714000_15.8.e095461.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2008.02283.x"},{"key":"2025123106455714000_15.8.e095461.17","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/jamainternmed.2023.6986","article-title":"First Trimester Use of Buprenorphine or Methadone and the Risk of Congenital Malformations","volume":"184","author":"Suarez","year":"2024","journal-title":"JAMA Intern Med"},{"key":"2025123106455714000_15.8.e095461.18","unstructured":"Seligman N , Rosenthal E , Berghella V . Opioid use disorder: overview of treatment during pregnancy - uptodate. Available: https:\/\/www.uptodate.com\/contents\/opioid-use-disorder-overview-of-treatment-during-pregnancy#H671768726 [Accessed 06 Oct 2024]."},{"key":"2025123106455714000_15.8.e095461.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2007.10.007"},{"key":"2025123106455714000_15.8.e095461.20","doi-asserted-by":"publisher","DOI":"10.1111\/acps.13088"},{"key":"2025123106455714000_15.8.e095461.21","doi-asserted-by":"crossref","first-page":"e202","DOI":"10.1055\/s-0040-1713787","article-title":"Methadone for Opioid Use Treatment during Pregnancy: Trends in Postpartum Dose Adjustments","volume":"10","author":"Ward","year":"2020","journal-title":"AJP Rep"},{"key":"2025123106455714000_15.8.e095461.22","unstructured":"British Columbia Centre on Substance Use, BC Ministry of Health, BC Ministry of . A guideline for the clinical management of opioid use disorder. british columbia centre on substance use. 2023."},{"key":"2025123106455714000_15.8.e095461.23","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1111\/add.16160","article-title":"Incremental expenditures attributable to daily dispensation and witnessed ingestion for opioid agonist treatment in British Columbia: 2014-20","volume":"118","author":"Nosyk","year":"2023","journal-title":"Addiction"},{"key":"2025123106455714000_15.8.e095461.24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1053\/j.semperi.2019.01.003","article-title":"Pharmacological treatment of opioid use disorder in pregnancy","volume":"43","author":"Rodriguez","year":"2019","journal-title":"Semin Perinatol"},{"key":"2025123106455714000_15.8.e095461.25","doi-asserted-by":"publisher","DOI":"10.1136\/fn.89.1.F33"},{"key":"2025123106455714000_15.8.e095461.26","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/0091450920969200","article-title":"Social Stigma and Perinatal Substance Use Services: Recognizing the Power of the Good Mother Ideal","volume":"48","author":"Nichols","year":"2021","journal-title":"Contemp Drug Probl"},{"key":"2025123106455714000_15.8.e095461.27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40352-015-0015-5","article-title":"Pregnant women and substance use: fear, stigma, and barriers to care","volume":"3","author":"Stone","year":"2015","journal-title":"Health Justice"},{"key":"2025123106455714000_15.8.e095461.28","doi-asserted-by":"publisher","DOI":"10.1111\/add.14947"},{"key":"2025123106455714000_15.8.e095461.29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203318"},{"key":"2025123106455714000_15.8.e095461.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1005359"},{"key":"2025123106455714000_15.8.e095461.31","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-036102","article-title":"Comparative effectiveness of buprenorphine-naloxone versus methadone for treatment of opioid use disorder: a population-based observational study protocol in British Columbia, Canada","volume":"10","author":"Piske","year":"2020","journal-title":"BMJ Open"},{"key":"2025123106455714000_15.8.e095461.32","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/j.jfda.2013.09.037","article-title":"Medication-assisted treatment for opioid addiction: methadone and buprenorphine","volume":"21","author":"Saxon","year":"2013","journal-title":"J Food Drug Anal"},{"key":"2025123106455714000_15.8.e095461.33","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","article-title":"External validity of randomised controlled trials: \u201cTo whom do the results of this trial apply?\u201d","volume":"365","author":"Rothwell","year":"2005","journal-title":"The Lancet"},{"key":"2025123106455714000_15.8.e095461.34","doi-asserted-by":"crossref","DOI":"10.1186\/s13010-019-0081-8","article-title":"The moral imperative to approve pregnant women\u2019s participation in randomized clinical trials for pregnancy and newborn complications","volume":"14","author":"Kaye","year":"2019","journal-title":"Philos Ethics Humanit Med"},{"key":"2025123106455714000_15.8.e095461.35","doi-asserted-by":"publisher","DOI":"10.1136\/emj.20.1.54"},{"key":"2025123106455714000_15.8.e095461.36","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-071108","article-title":"Target trial emulation: applying principles of randomised trials to observational studies","volume":"378","author":"Matthews","year":"2022","journal-title":"BMJ"},{"key":"2025123106455714000_15.8.e095461.37","doi-asserted-by":"crossref","unstructured":"Leshner AI , Mancher M , eds. Medications for Opioid Use Disorder Save Lives. Washington, D.C: National Academies Press, 2019.","DOI":"10.17226\/25310"},{"key":"2025123106455714000_15.8.e095461.38","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00001648-200009000-00012","article-title":"Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men","volume":"11","author":"Hern\u00e1n","year":"2000","journal-title":"Epidemiology (Sunnyvale)"},{"key":"2025123106455714000_15.8.e095461.39","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1144"},{"key":"2025123106455714000_15.8.e095461.40","doi-asserted-by":"publisher","DOI":"10.1016\/0898-1221(87)90238-0"},{"key":"2025123106455714000_15.8.e095461.41","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005285815569"},{"key":"2025123106455714000_15.8.e095461.42","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1080\/03610929408831393","article-title":"Correcting for non-compliance in randomized trials using structural nested mean models","volume":"23","author":"Robins","year":"1994","journal-title":"Communications in Statistics - Theory and Methods"},{"key":"2025123106455714000_15.8.e095461.43","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/add.16473","article-title":"Target trial emulation for comparative effectiveness research with observational data: Promise and challenges for studying medications for opioid use disorder","volume":"119","author":"Christine","year":"2024","journal-title":"Addiction"},{"key":"2025123106455714000_15.8.e095461.44","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.21383"},{"key":"2025123106455714000_15.8.e095461.45","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwv214"},{"key":"2025123106455714000_15.8.e095461.46","unstructured":"Wood ME , Latour CD , Petito LC . Treatments for pregestational chronic conditions during pregnancy: emulating a target trial with a treatment decision design. 2023."},{"key":"2025123106455714000_15.8.e095461.47","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4107"},{"key":"2025123106455714000_15.8.e095461.48","doi-asserted-by":"crossref","first-page":"102726","DOI":"10.1016\/j.drugpo.2020.102726","article-title":"How simulation modeling can support the public health response to the opioid crisis in North America: Setting priorities and assessing value","volume":"88","author":"Bansback","year":"2021","journal-title":"Int J Drug Policy"},{"key":"2025123106455714000_15.8.e095461.49","unstructured":"British Columbia Centre on Substance Use and B.C. Ministry of Health . A guideline for the clinical management of opioid use disorder. 2017."},{"key":"2025123106455714000_15.8.e095461.50","doi-asserted-by":"crossref","first-page":"108799","DOI":"10.1016\/j.drugalcdep.2021.108799","article-title":"Characterizing opioid agonist treatment discontinuation trends in British Columbia, Canada, 2012-2018","volume":"225","author":"Krebs","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"2025123106455714000_15.8.e095461.51","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.m772","article-title":"Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study","volume":"368","author":"Pearce","year":"2020","journal-title":"BMJ"},{"key":"2025123106455714000_15.8.e095461.52","unstructured":"World health organization. Maternal Deaths; 2024."},{"key":"2025123106455714000_15.8.e095461.53","doi-asserted-by":"crossref","first-page":"862","DOI":"10.7326\/M23-2038","article-title":"Metformin Use in the First Trimester of Pregnancy and Risk for Nonlive Birth and Congenital Malformations: Emulating a Target Trial Using Real-World Data","volume":"177","author":"Chiu","year":"2024","journal-title":"Ann Intern Med"},{"key":"2025123106455714000_15.8.e095461.54","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/bdr2.2112","article-title":"Validation of case definition algorithms for the ascertainment of congenital anomalies","volume":"115","author":"Nava de Escalante","year":"2023","journal-title":"Birth Defects Res"},{"key":"2025123106455714000_15.8.e095461.55","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-018-2519-5","article-title":"Improved adherence adjustment in the Coronary Drug Project","volume":"19","author":"Murray","year":"2018","journal-title":"Trials"},{"key":"2025123106455714000_15.8.e095461.56","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076336","article-title":"Effect of Risk Mitigation Guidance opioid and stimulant dispensations on mortality and acute care visits during dual public health emergencies: retrospective cohort study","volume":"384","author":"Slaunwhite","year":"2024","journal-title":"BMJ"},{"key":"2025123106455714000_15.8.e095461.57","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1002\/sim.8120","article-title":"Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV-positive individuals","volume":"38","author":"Caniglia","year":"2019","journal-title":"Stat Med"},{"key":"2025123106455714000_15.8.e095461.58","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/EDE.0000000000001601","article-title":"Emulating Target Trials to Avoid Immortal Time Bias - An Application to Antibiotic Initiation and Preterm Delivery","volume":"34","author":"Caniglia","year":"2023","journal-title":"Epidemiology (Sunnyvale)"},{"key":"2025123106455714000_15.8.e095461.59","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/2632084320961043","article-title":"Causal survival analysis: A guide to estimating intention-to-treat and per-protocol effects from randomized clinical trials with non-adherence","volume":"2","author":"Murray","year":"2021","journal-title":"Research Methods in Medicine & Health Sciences"},{"key":"2025123106455714000_15.8.e095461.60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2017.11.021"},{"key":"2025123106455714000_15.8.e095461.61","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/EDE.0000000000001144","article-title":"Long-term Exposure to Neighborhood Deprivation and Intimate Partner Violence Among Women: A UK Birth Cohort Study","volume":"31","author":"Yakubovich","year":"2020","journal-title":"Epidemiology (Sunnyvale)"},{"key":"2025123106455714000_15.8.e095461.62","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyu149"},{"key":"2025123106455714000_15.8.e095461.63","doi-asserted-by":"publisher","DOI":"10.24095\/hpcdp.38.6.02"},{"key":"2025123106455714000_15.8.e095461.64","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1097\/EDE.0000000000000864","article-title":"Web Site and R Package for Computing E-values","volume":"29","author":"Mathur","year":"2018","journal-title":"Epidemiology (Sunnyvale)"},{"key":"2025123106455714000_15.8.e095461.65","unstructured":"Government of Canada IAP on RE . Tri-council policy statement: ethical conduct for research involving humans \u2013 tcps 2 (2018). 2019. Available: https:\/\/ethics.gc.ca\/eng\/policy-politique_tcps2-eptc2_2018.html [Accessed 28 Apr 2024]."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-095461","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T14:46:52Z","timestamp":1767192412000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-095461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":65,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,10]]},"published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1136\/bmjopen-2024-095461"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-095461","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]}}}